🎉 M&A multiples are live!
Check it out!

Amplia Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Amplia Therapeutics and similar public comparables like Julphar, Vivoryon Therapeutics, and Benevolent AI.

Amplia Therapeutics Overview

About Amplia Therapeutics

Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure-play inhibitor, while the second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways - VEGFR3 and FLT3.


Founded

2013

HQ

Australia
Employees

n/a

Website

ampliatx.com

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$14.6M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Amplia Therapeutics Financials

Amplia Therapeutics has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Amplia Therapeutics achieved revenue of n/a and an EBITDA of -$2.7M.

Amplia Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Amplia Therapeutics valuation multiples based on analyst estimates

Amplia Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$3.9M -$2.7M XXX XXX XXX
EBITDA Margin NaN% NaN% XXX XXX XXX
Net Profit -$2.3M -$3.9M XXX XXX XXX
Net Margin NaN% NaN% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Amplia Therapeutics Stock Performance

As of March 14, 2025, Amplia Therapeutics's stock price is AUD 0 (or $0).

Amplia Therapeutics has current market cap of AUD 27.5M (or $17.4M), and EV of AUD 23.0M (or $14.6M).

See Amplia Therapeutics trading valuation data

Amplia Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$14.6M $17.4M XXX XXX XXX XXX n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Amplia Therapeutics Valuation Multiples

As of March 14, 2025, Amplia Therapeutics has market cap of $17.4M and EV of $14.6M.

Amplia Therapeutics's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Amplia Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Amplia Therapeutics and 10K+ public comps

Amplia Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $14.6M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA n/a XXX XXX XXX
P/E n/a XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF n/a XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Amplia Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Amplia Therapeutics Valuation Multiples

Amplia Therapeutics's NTM/LTM revenue growth is n/a

Amplia Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.

Over next 12 months, Amplia Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Amplia Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Amplia Therapeutics and other 10K+ public comps

Amplia Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth -29% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee n/a XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Amplia Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Amplia Therapeutics M&A and Investment Activity

Amplia Therapeutics acquired  XXX companies to date.

Last acquisition by Amplia Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Amplia Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Amplia Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Amplia Therapeutics

When was Amplia Therapeutics founded? Amplia Therapeutics was founded in 2013.
Where is Amplia Therapeutics headquartered? Amplia Therapeutics is headquartered in Australia.
Is Amplia Therapeutics publicy listed? Yes, Amplia Therapeutics is a public company listed on ASX.
What is the stock symbol of Amplia Therapeutics? Amplia Therapeutics trades under ATX ticker.
When did Amplia Therapeutics go public? Amplia Therapeutics went public in 2013.
Who are competitors of Amplia Therapeutics? Similar companies to Amplia Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Amplia Therapeutics? Amplia Therapeutics's current market cap is $17.4M
Is Amplia Therapeutics profitable? Yes, Amplia Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.